Xu H, Gonzalo J A, St Pierre Y, Williams I R, Kupper T S, Cotran R S, Springer T A, Gutierrez-Ramos J C
Center for Blood Research, Harvard Medical School, Boston, Massachusetts.
J Exp Med. 1994 Jul 1;180(1):95-109. doi: 10.1084/jem.180.1.95.
Intercellular adhesion molecule 1 (ICAM-1) is one of three immunoglobulin superfamily members that bind to the integrins lymphocyte function associated 1 (LFA-1) and Mac-1 on leukocytes. We have generated mice that are genetically and functionally deficient in ICAM-1. These mice have elevated numbers of circulating neutrophils and lymphocytes, as well as diminished allogeneic T cell responses and delayed type hypersensitivity. Mutant mice are resistant to lethal effects of high doses of endotoxin (lipopolysaccharide [LPS]), and this correlates with a significant decrease in neutrophil infiltration in the liver. Production of inflammatory cytokines such as tumor necrosis factor alpha or interleukin 1 is normal in ICAM-1-deficient mice, and thus protection appears to be related to a diminution in critical leukocyte-endothelial interactions. After sensitization with D-galactosamine (D-Gal), ICAM-1-deficient mice are resistant to the lethal effect of low doses of exotoxin (Staphylococcus aureus enterotoxin B [SEB]), which has been shown to mediate its toxic effects via the activation of specific T cells. In this model, ICAM-1-mediated protection against SEB lethality correlates with a decrease in the systemic release of inflammatory cytokines, as well as with prevention of extensive hepatocyte necrosis and hemorrhage. ICAM-1-deficient mice sensitized with D-Gal, however, are not protected from lethality when challenged with low doses of endotoxin (LPS). These studies show that the different contribution of ICAM-1 in the activation of either T cells or macrophages is decisive for the fatal outcome of the shock in these two models. This work suggests that anti-ICAM-1 therapy may be beneficial in both gram-positive and -negative septic shock, either by reducing T cell activation or by diminishing neutrophil infiltration.
细胞间黏附分子1(ICAM-1)是免疫球蛋白超家族的三个成员之一,可与白细胞上的整合素淋巴细胞功能相关抗原1(LFA-1)和巨噬细胞抗原1(Mac-1)结合。我们已培育出ICAM-1基因和功能缺陷的小鼠。这些小鼠循环中的中性粒细胞和淋巴细胞数量增加,同种异体T细胞反应减弱,迟发型超敏反应延迟。突变小鼠对高剂量内毒素(脂多糖[LPS])的致死作用具有抗性,这与肝脏中中性粒细胞浸润的显著减少相关。在ICAM-1缺陷小鼠中,肿瘤坏死因子α或白细胞介素1等炎性细胞因子的产生正常,因此这种保护作用似乎与关键的白细胞-内皮细胞相互作用的减少有关。用D-半乳糖胺(D-Gal)致敏后,ICAM-1缺陷小鼠对低剂量外毒素(金黄色葡萄球菌肠毒素B[SEB])的致死作用具有抗性,已证明该外毒素通过激活特定T细胞介导其毒性作用。在这个模型中,ICAM-1介导的对SEB致死性的保护作用与炎性细胞因子全身释放的减少以及广泛肝细胞坏死和出血的预防相关。然而,用D-Gal致敏的ICAM-1缺陷小鼠在受到低剂量内毒素(LPS)攻击时并不能免受致死作用。这些研究表明,ICAM-1在激活T细胞或巨噬细胞中的不同作用对于这两种模型中休克的致命结局起决定性作用。这项工作表明,抗ICAM-1疗法可能对革兰氏阳性和阴性脓毒症休克均有益,要么通过减少T细胞激活,要么通过减少中性粒细胞浸润。